Answers are grounded in this paper and cite their sources.
BACKGROUND: Like other medicinal products, vaccines are not free from adverse reactions. On January 2, 2021, the Drugs Controller General of India granted permission for restricted emergency use of a vaccine, namely COVISHIELD (ChAdOx1 nCoV-19 vaccine). There was a lack of safety data in the Indian population after restricted emergency approval of the vaccine. The present study addresses the assessment of adverse events following immunizations (AEFIs) among the beneficiaries receiving the COVISHIELD vaccine. METHODOLOGY: A prospective observational cohort study was conducted on eligible beneficiaries attending the coronavirus disease 2019 (COVID-19) vaccination center in our institute. The study was conducted from April 2021 to March 2022. RESULTS: Three hundred and thirty participants completed the study, with a response rate of 97.92%. The most frequently reported AEFI after the first dose was injection site pain. No AEFI was reported after 3 months of the second dose of vaccination. After the first dose of vaccination, fever was significant ( P = 0.009) in male participants and injection site pain was significantly common ( P = 0.015) in participants with no comorbidity. After the second dose of vaccination, injection site pain was significant ( P = 0.008) in those participants whose age was ≤60 years, and injection site pain was significant (<0.0001) in those participants who did not have any comorbidity. CONCLUSION: The majority of reactions belong to the minor category which includes injection site pain, fever, and myalgia. Thus, the study findings provide inputs for making regulatory decisions for vaccines used for COVID-19.
No takes yet. Share an insight, caveat, or question.
Gupta et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: